Wynne, Chris <br/><br/>
Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta  [electronic resource] 

 -  Pharmacology research & perspectives  04 2020 
 - e00578 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2052-1707 
<br/><br/><label>Standard No.: </label>10.1002/prp2.578  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies--blood<br/>Biosimilar Pharmaceuticals--adverse effects<br/>Double-Blind Method<br/>Female<br/>Filgrastim--adverse effects<br/>Healthy Volunteers<br/>Humans<br/>Male<br/>Polyethylene Glycols--adverse effects<br/>Young Adult